Cue Biopharma
Cue Biopharma's revenue rose 195.8% to $28 million in fiscal 2025. Its operating margin was −96.7%, up from −446.9% a year earlier. Free cash flow was −$22 million. The diluted share count rose 68.2%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Cue Biopharma does
Cue Biopharma is a biotech company developing injectable drugs that aim to adjust specific parts of the immune system, called T cells, rather than boosting or suppressing it across the board. It is clinical-stage, which means it has no approved products and earns no revenue from selling medicines. Since July 2024 it has focused on autoimmune and inflammatory diseases, in which the immune system attacks the body's own tissue.
Its lead drug candidate, CUE-401, aims to restore immune balance by increasing regulatory T cells, the cells that keep the immune system in check. It has been tested only in animals so far, and Cue planned to file to start human trials in the second quarter of 2026. A second candidate, CUE-501, aims to direct existing T cells to destroy B cells that cause autoimmune disease; in April 2025 Cue licensed it to the drugmaker Boehringer Ingelheim. Its cancer candidates, CUE-101 and CUE-102, were licensed to ImmunoScape in November 2025. All of Cue's revenue so far has come from agreements with partners like these.
The company is based in Boston, Massachusetts, relies on outside firms to make its drugs and run its trials, and had 29 full-time employees at the end of 2025.
Its biggest risks, as it describes them
- Its recurring losses raise substantial doubt about whether it can keep operating.
- Its drug candidates may fail in testing or show side effects not seen in animal studies.
- Relying on partners such as Boehringer Ingelheim, whose deals may not bring the benefits it expects and limit its own research.
- Relying fully on outside firms to make its drug supplies, some from a single source, and to run its trials.
- Competition from larger drugmakers working on treatments for the same diseases.
Income statement
Cue Biopharma lost money in fiscal 2025: a net loss of $27 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 64 | 76 | 48 | 22 | 27 |
| Debt incl. finance leases | 0 | 8 | 4 | — | 0 |
| Net debt (negative means net cash) | −64 | −68 | −44 | — | −27 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | 0.1x | 0.1x | — | 0.0x |
| Interest coverage | — | −488.3x | −521.5x | −415.0x | −265.5x |
| Current ratio | 5.3x | 6.7x | 3.0x | 1.8x | 2.7x |
| Quick ratio | 5.3x | 6.7x | 3.0x | 1.8x | 2.7x |
Cash flow
Projections
Project Cue Biopharma's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $99,719 of Cue Biopharma shares on the open market, and 3 insiders sold $2.0 million.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 13, 2026 | Shao-Lee LinChief Executive Officer, Director | Sold | 18,258 | $28.62 | $522,573 | Form 4 |
| Aug 13, 2026 | Sumita RayChief Legal Compliance Officer | Sold | 8,829 | $30.09 | $265,628 | Form 4 |
| Aug 13, 2026 | Michael Vincent MeluzioVP, Prin. Accounting Officer | Sold | 5,628 | $30.09 | $169,324 | Form 4 |
| Aug 12, 2026 | Shao-Lee LinChief Executive Officer, Director | Sold | 40,000 | $27.10 | $1.1 million | Form 4 |
| Dec 30, 2025 | Pasha SarrafDirector | Bought | 323,857 | $0.31 | $99,719 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 4 of 8 | — | — |
| Rule of 40 | −386.9% | −322.7% | 116.1% |
| Altman Z'' | −16.40 | −39.70 | −27.27 |
| Accruals ratio | −14.1% | −9.3% | −13.2% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | — | — |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 4 of 8 | — | — |
Compare
Put Cue Biopharma side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Cue Biopharma | FY25 | 195.8% | −96.7% | −79.6% | — | — | — | |
| Celularity | FY25 | −51.0% | −230.9% | — | — | — | — | Compare |
| Scilex | FY25 | −46.5% | −1,143.7% | 12.2% | — | — | 3 | Compare |
| Foghorn Therapeutics | FY25 | 36.8% | −279.5% | −278.7% | — | — | 2 | Compare |
| Verastem | FY25 | 209.1% | −550.3% | — | — | — | — | Compare |
9 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | — | 1 | 4 | 3 | 15 | 1 | 6 | 9 | 28 |
| Revenue growth | — | — | 202.7% | −8.8% | 373.7% | −91.7% | 341.0% | 69.2% | 195.8% |
| Gross profit | — | — | — | — | — | — | — | — | — |
| Research and development | 19 | 28 | 28 | 34 | 41 | 39 | 41 | 36 | 38 |
| Operating income | −23 | −39 | −37 | −45 | −44 | −53 | −52 | −42 | −27 |
| Net income | −23 | −39 | −37 | −45 | −44 | −53 | −51 | −41 | −27 |
| Diluted EPS (US$) | −2.16 | −1.94 | −1.66 | −1.56 | −1.41 | −1.49 | −1.11 | −0.72 | −0.28 |
| Diluted shares (millions) | 11 | 20 | 22 | 29 | 31 | 36 | 46 | 56 | 95 |
| Cash flow | |||||||||
| Cash from operations | −12 | −26 | −31 | −32 | −39 | −42 | −40 | −36 | −22 |
| Capital expenditure | 1 | 2 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Free cash flow | −13 | −28 | −31 | −33 | −40 | −42 | −40 | −36 | −22 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 3 | 7 | 6 | 10 | 12 | 10 | 8 | 7 | 5 |
| Balance sheet at fiscal year end | |||||||||
| Cash and short-term investments | 64 | 39 | 59 | 85 | 64 | 76 | 48 | 22 | 27 |
| Debt incl. finance leases | — | — | — | — | 0 | 8 | 4 | — | 0 |
| Total assets | 67 | 45 | 72 | 100 | 83 | 91 | 62 | 32 | 42 |
| Total liabilities | 5 | 11 | 17 | 21 | 18 | 26 | 24 | 15 | 16 |
| Shareholders' equity | 62 | 34 | 55 | 79 | 66 | 66 | 37 | 18 | 26 |
| Margins and ratios | |||||||||
| Gross margin | — | — | — | — | — | — | — | — | — |
| Operating margin | — | −3,386.7% | −1,063.2% | −1,428.0% | −292.6% | −4,275.1% | −949.9% | −446.9% | −96.7% |
| Net margin | — | −3,411.5% | −1,061.2% | −1,419.8% | −295.6% | −4,257.8% | −924.1% | −438.0% | −96.8% |
| Free cash flow margin | — | −2,473.8% | −891.9% | −1,049.0% | −266.0% | −3,371.7% | −727.9% | −391.9% | −79.6% |
| Rule of 40 (growth + FCF margin) | — | — | −689.2% | −1,057.8% | 107.6% | −3,463.3% | −386.9% | −322.7% | 116.1% |
| Return on capital | — | — | — | — | — | — | — | — | — |
| Return on equity | — | −81.6% | −82.9% | −67.1% | −61.2% | −80.8% | −98.7% | −149.0% | −121.1% |
| Return on assets | — | −69.4% | −62.8% | −52.3% | −48.3% | −60.7% | −66.4% | −86.8% | −71.5% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — |